ERAS
Erasca, Inc.
$17.90
-0.63 (-3.40%)
At close · Jul 13
Market Cap
$6.06B
Shares
310,984,542
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$124.55M
+23%
FY2025
Diluted EPS
-$0.44
+36.2%
FY2025
Operating Cash Flow
-$95.46M
+12.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $94.15M | $92.85M | $115.36M | $103.82M | $112.46M | $73.92M | $29.55M | |
| $39.54M | $38.55M | $41.73M | $37.7M | $32.99M | $22.62M | $7.96M | |
| $3.01M | $3.11M | $3.81M | $3.73M | $2.64M | $829K | $540K | |
| $293.19M | $140.91M | $179.59M | $141.53M | $247.45M | $124.88M | $109.25M | |
| -$293.19M | -$140.91M | -$179.59M | -$141.53M | -$247.45M | -$124.88M | -$109.25M | |
| $16.17M | $16.36M | $17.94M | $16.48M | $4.65M | $2.12M | $7.59M | |
| — | -$124.55M | -$161.65M | — | — | — | — | |
| — | $0 | $0 | — | — | — | — | |
| -$277.02M | -$124.55M | -$161.65M | -$125.04M | -$242.81M | -$122.76M | -$101.66M | |
| -$278.35M | -$124.32M | -$161.32M | -$123.92M | -$243.68M | -$122.93M | -$101.67M | |
| USD/shares | — | -$0.44 | -$0.69 | -$0.83 | -$1.99 | -$1.85 | — |
| USD/shares | — | -$0.44 | -$0.69 | -$0.83 | -$1.99 | -$1.85 | — |
| shares | — | 283.53M | 233.82M | 150.18M | 122.02M | 66.29M | 21.04M |
| shares | — | 283.53M | 233.82M | 150.18M | 122.02M | 66.29M | 21.04M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.34×
EV/EBIT
—
Biotechnology median 25.45×
P/E (TTM)
—
Biotechnology median 7.54×